Stockholm, November 28, 2022 – Intervacc AB (publ) announces today that Strangvac is now available for sale in Poland. Dechra Pharmaceuticals PLC distribute the vaccine in Poland and in a number of other European countries.
Poland with its approximately 300,000 horses, it has a long tradition in equestrian sport, and outbreaks of the highly contagious infectious disease affect horses and horse owners across the country.
“We have investigated outbreaks of strangulation in horses for many years, helping to track the causative agent, Streptococcus equi, as it spreads through equine populations around the world, including Poland. Strangvac launch in Poland gives us a new tool to reduce the health and economic impact of this terrible disease while keeping our horses safe.” says Dr Lucjan Witkowski from Institute of Veterinary Medicine at the University of Warsaw.
“Strangvac is approved for sale and marketing in the EU as well UK and Norway. Strangvac was launched in Sweden, Denmarkthe UK, France, Germanythe Benelux region, Austria, Ireland and now and in Poland. Outbreaks of equine strangulation occur regularly and the disease causes great suffering and economic costs in and across the region Europe. Poland is an important equine market and this is a significant milestone for our continued rollout Europe.” comments Andreas AnderssonCEO of Intervacc.
For more information, please contact:
Telephone: +46-8-120 10 601, mobile +46-73-335 99 70
Email: [email protected]
The information was submitted for publication, through the agency of the contact person mentioned above at November 28, 202211.45 CET.
Intervacc AB is a Swedish animal health company that develops vaccines for animals. The company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institute and Swedish University of Agricultural Research where the foundations of the Company’s research and development activity were laid. The Intervacc the stock has been listed on the Nasdaq First North Growth Market since then April 2017 with Eminova Fondkommission AB as an authorized advisor.
Certified Adviser contact information
Eminova Fondkommission AB
E-mail: [email protected], Phone: +46 (0)8 – 684 211 10
(c) 2022 Severance. All rights reserved., source Press releases – English